Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
γδ T cells in Cancer
We acknowledge the initiation and support of this Research Topic by the International Union of Immunological Societies (IUIS). Dr. Dieter Kabelitz currently serves as the chairman for the IUIS Education Committee. Topic Editor Prof. Ilan Bank is Chief Scientific Officer of GammaCell Bio-Technologies Ltd. Topic Editor Prof. Jurgen Kuball is co-founder and scientific advisor of GADETA. Topic Editor Prof. Bruno Silva-Santos is co-founder of Lymphact S.A., a company now owned by GammaDelta Therapeutics. All other Topic Editors declare no competing interests with regards to the Research Topic subject.
The EBMT Handbook
None
Adoptive Immunotherapy
An authoritative collection of optimal techniques for producing and characterizing the immunologically active cells and effector molecules now gaining wide use in the clinical treatment of patients. Taking advantage of the latest technologies, the authors present readily reproducible experimental protocols for the study of dendritic cells, T cells, monoclonal antibodies, and bone marrow transplantation. The emphasis is on preclinicical and clinical applications and on the progress of selected approaches in clinical trials. Additional chapters cover the molecular definition of target antigens, mathematical modeling approaches to immunotherapy, and the utilization of regulatory T cells. The protocols make it possible to study the adoptive transfer of tailored antigen-specific immune cells and to improve the clinical application of adoptive immunotherapy.
Innate Immune Cell Therapy of Cancer
Adoptive cellular immunotherapy of cancer, particularly chimeric antigen receptor-transduced T cell (CAR-T) therapies, have enjoyed an explosion of clinical trials and translational and basic research in the past decade. The concept and design of the CAR, though originally intended to optimize targeting of innate natural killer cells (NK cells) to tumor-specific antigens, was laterally applied in the past decade to conventional autologous and later third-party allogeneic T cells with first-in-kind successes in leukemia immunotherapy in both adults and children. This approach also spawned the development of an entire industry focused on cancer immunotherapy, laying the foundation for the current paradigm shifts away from toxic chemo/radiotherapy to immune targeting. Aside from cytokine-release toxicities, specific obstacles plaguing existing CAR-T cell therapies include suboptimal killing by fatigued or senescent autologous patient-derived T cells derived, acquisition of tumor resistance to T-cell based immune therapies, and graft-versus-host disease (GVHD) associated with allogeneic conventional T cell therapies.
Innovations in Development, Translational Research and Manufacturing of CAR T cells
Immunotherapy with genetically engineered immune cell products is a transformative treatment modality with potential applications in various fields of medicine. A prime example is chimeric antigen receptor (CAR)-modified T cells in hematology and oncology, and the advent of CAR T cell therapies to treat infectious diseases, autoimmune disorders, and cardiovascular diseases. The medical need and demand from patients and caregivers require radical innovations to accelerate and improve pre-clinical development and clinical translation, provision of gene-transfer vectors, and immune cell product manufacturing as well as a critical reflection and discussion on ethical and socioeconomic aspects. T...
Recent Advances in γδ T Cell Biology: New Ligands, New Functions, and New Translational Perspectives
Gamma/delta (γδ) T-cells are a small subset of T-lymphocytes in the peripheral circulation but constitute a major T-cell population at other anatomical localizations such as the epithelial tissues. In contrast to conventional α/β T-cells, the available number of germline genes coding for T-cell receptor (TCR) variable elements of γδ T-cells is very small. Moreover, there is a prefential localization of γδ T-cells expressing given Vgamma and Vdelta genes in certain tissues. In humans, γδ T-cells expressing the Vg9Vd2-encoded TCR account for anywhere between 50 and >95% of peripheral blood γδ T-cells, whereas cells expressing non-Vd2 genes dominate in mucosal tissues. In mice, ther...
The EBMT/EHA CAR-T Cell Handbook
This first open access European CAR-T Handbook, co-promoted by the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), covers several aspects of CAR-T cell treatments, including the underlying biology, indications, management of side-effects, access and manufacturing issues. This book, written by leading experts in the field to enhance readers’ knowledge and practice skills, provides an unparalleled overview of the CAR-T cell technology and its application in clinical care, to enhance readers’ knowledge and practice skills.
